Clinical trials: Active Population
Atherosclerosis
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing.
- Trial name
- NCT00695305
- Testing
- rilapladib, 18F Fluorodeoxylucose (FDG)-PET
- Where
- 10 sites in United States
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis
Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, positive drug parallel-group controlled clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of HLX03 and adalimumab (Humira) in subjects with…
- Trial name
- NCT03316781
- Testing
- HLX03, adalimumab
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Shanghai Henlius Biotech
Type 2 Diabetes Mellitus
Study of Rivoglitazone in Type 2 Diabetes Mellitus
This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy.
- Trial name
- NCT00484198
- Testing
- Pioglitazone, Rivoglitazone
- Where
- 183 sites in United States, Argentina and 16 more
- Volunteers
- 1,912 people
- Sponsor
- Daiichi Sankyo
Crohn's Disease
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
- Trial name
- DUET-CD (NCT05242471)
- Testing
- Guselkumab, Golimumab, JNJ-78934804
- Where
- 456 sites in United States, Australia and 34 more
- Volunteers
- 703 people
- Sponsor
- Janssen Research & Development, LLC
Open Angle Glaucoma, Ocular Hypertension
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.
- Trial name
- NCT06666855
- Testing
- DE-117B Eye Drops, Latanoprost
- Where
- 24 sites in China
- Volunteers
- 345 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma
To compare the efficacy and safety of the fixed combination asthma drug Flutiform HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, in adult and adolescent patients with mild to…
- Trial name
- NCT00394199
- Testing
- Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
- Where
- 41 sites in United States, Canada
- Volunteers
- 357 people
- Sponsor
- SkyePharma AG
Colitis, Ulcerative
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction…
- Trial name
- QUASAR Jr (NCT06260163)
- Testing
- Guselkumab Subcutaneous, Guselkumab Intravenous
- Where
- 61 sites in United States, Australia and 11 more
- Volunteers
- 112 people
- Sponsor
- Janssen Research & Development, LLC
Colitis, Ulcerative
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score (TMS) of 4-11 inclusive, with an endoscopic…
- Trial name
- NCT02762500
- Testing
- LYC-30937-EC
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Lycera Corp.
Urinary Bladder, Overactive
A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
Solifenacin succinate as a tablet formulation is already on the market for the treatment of symptoms of overactive bladder in adults.
- Trial name
- LION (NCT01565707)
- Testing
- Solifenacin Succinate Suspension, Urotherapy
- Where
- 46 sites in United States, Belgium and 14 more
- Volunteers
- 189 people
- Sponsor
- Astellas Pharma Europe B.V.
Crohn's Disease
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.
- Trial name
- NCT00562887
- Testing
- ABT-874
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Abbott
Infant ALL
A Clinical Trial on the Effect of Infant Formula Consumption on Growth, Immune Parameters, and Gut Health in Healthy Term Infants
The goal of this clinical trial is to study growth (weight gain per day) in healthy full-term infants who consume the investigational infant formula containing beneficial ingredients against infants consuming a control infant…
- Trial name
- NCT07867509
- Testing
- Infant Formula, Breastfeeding
- Volunteers
- 387 people, healthy volunteers welcome
- Sponsor
- FrieslandCampina
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
The purpose of the study is to assess the efficacy, safety, and tolerability of two doses of laquinimod compared to Avonex®
- Trial name
- LIBRETTO (NCT01975298)
- Testing
- Laquinimod, Avonex®
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
- Trial name
- BE AGILE (NCT02963506)
- Testing
- Bimekizumab
- Where
- 74 sites in United States, Bulgaria and 8 more
- Volunteers
- 303 people
- Sponsor
- UCB Biopharma S.P.R.L.
Respiratory Tract Infections, Fever
Placebo and Active Controlled Study to Compare the Antipyretic Efficacy of Aspirin® in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin
This study is addressed to patients suffering from an acute febrile upper respiratory tract infection suspected to be of viral origin.
- Trial name
- NCT01464944
- Testing
- Acetylsalicylic acid (Aspirin, BAYE4465), Paracetamol
- Where
- 9 sites in Russia, Ukraine
- Volunteers
- 392 people
- Sponsor
- Bayer
Venous Thrombosis, Deep Vein Thrombosis
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for…
- Trial name
- NCT00839163
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Enoxaparin/Vitamin K-Antagonist
- Where
- 110 sites in Australia, Austria and 17 more
- Volunteers
- 613 people
- Sponsor
- Bayer
Systemic Lupus Erythematosus (SLE)
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
- Trial name
- NCT02804763
- Testing
- Dapirolizumab pegol (DZP)
- Where
- 71 sites in United States, Bulgaria and 11 more
- Volunteers
- 182 people
- Sponsor
- UCB Biopharma S.P.R.L.
Benign Prostate Hyperplasia
A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia
The purpose of this study is to compare the efficacy of ASP4901 with placebo in patients with benign prostatic hyperplasia. The safety and tolerability of ASP4901 will also be evaluated.
- Trial name
- NCT02038868
- Testing
- ASP4901, Tamsulosin
- Where
- 2 sites in Japan
- Volunteers
- 320 people
- Sponsor
- Astellas Pharma Inc
Fatigue in Multiple Sclerosis
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
This study evaluated the effect of an individualized web-based physical training in fingolimod -treated patients.
- Trial name
- PACE (NCT01490840)
- Testing
- Physical exercise
- Where
- 32 sites in Germany
- Volunteers
- 178 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
- Trial name
- NCT00976391
- Testing
- albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
- Where
- 209 sites in United States, Brazil and 12 more
- Volunteers
- 586 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.